Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

16 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Modeling the acute mucosal toxicity to fractionated radiotherapy combined with the ATM inhibitor WSD0628.
Garcia DA, Rathi S, Connors MA, Grams M, Vaubel RA, Bakken KK, Ott LL, Carlson BL, Hu Z, Decker PA, Eckel-Passow JE, Burgenske DM, Zhong W, Trzasko JD, Herman MG, Elmquist WF, Remmes NB, Sarkaria JN. Garcia DA, et al. Among authors: bakken kk. Mol Cancer Ther. 2024 Nov 19. doi: 10.1158/1535-7163.MCT-24-0664. Online ahead of print. Mol Cancer Ther. 2024. PMID: 39559836
DNA-PK inhibition shows differential radiosensitization in orthotopic GBM PDX models based on DDR pathway deficits.
Dragojevic S, Smith EJ, Regan MS, Stopka SA, Baquer G, Xue Z, Zhang W, Connors MA, Kloeber JA, Hu Z, Bakken KK, Ott LL, Carlson BL, Burgenske DM, Decker PA, Tian S, Gupta SK, Laverty DJ, Eckel-Passow JE, Elmquist WF, Agar NYR, Nagel ZD, Sarkaria JN, Callaghan CM. Dragojevic S, et al. Among authors: bakken kk. Mol Cancer Ther. 2024 Oct 23. doi: 10.1158/1535-7163.MCT-24-0003. Online ahead of print. Mol Cancer Ther. 2024. PMID: 39440433
Factors Influencing the Central Nervous System (CNS) Distribution of the Ataxia Telangiectasia Mutated and Rad3-Related Inhibitor Elimusertib (BAY1895344): Implications for the Treatment of CNS Tumors.
Rathi S, Mladek AC, Oh JH, Dragojevic S, Burgenske DM, Zhang W, Talele S, Zhang W, Bakken KK, Carlson BL, Connors MA, He L, Hu Z, Sarkaria JN, Elmquist WF. Rathi S, et al. Among authors: bakken kk. J Pharmacol Exp Ther. 2024 Oct 18;391(2):346-360. doi: 10.1124/jpet.123.002002. J Pharmacol Exp Ther. 2024. PMID: 39284626
Aberrant ATM signaling and homology-directed DNA repair as a vulnerability of p53-mutant GBM to AZD1390-mediated radiosensitization.
Chen J, Laverty DJ, Talele S, Bale A, Carlson BL, Porath KA, Bakken KK, Burgenske DM, Decker PA, Vaubel RA, Eckel-Passow JE, Bhargava R, Lou Z, Hamerlik P, Harley B, Elmquist WF, Nagel ZD, Gupta SK, Sarkaria JN. Chen J, et al. Among authors: bakken kk. Sci Transl Med. 2024 Feb 14;16(734):eadj5962. doi: 10.1126/scitranslmed.adj5962. Epub 2024 Feb 14. Sci Transl Med. 2024. PMID: 38354228
Differential Distribution of the DNA-PKcs Inhibitor Peposertib Selectively Radiosensitizes Patient-derived Melanoma Brain Metastasis Xenografts.
Ji J, Dragojevic S, Callaghan CM, Smith EJ, Talele S, Zhang W, Connors MA, Mladek AC, Hu Z, Bakken KK, Sarkaria PP, Carlson BL, Burgenske DM, Decker PA, Rashid MA, Jang MH, Gupta SK, Eckel-Passow JE, Elmquist WF, Sarkaria JN. Ji J, et al. Among authors: bakken kk. Mol Cancer Ther. 2024 May 2;23(5):662-671. doi: 10.1158/1535-7163.MCT-23-0552. Mol Cancer Ther. 2024. PMID: 38224566 Free PMC article.
WSD-0922, a novel brain-penetrant inhibitor of epidermal growth factor receptor, promotes survival in glioblastoma mouse models.
Conage-Pough JE, Stopka SA, Oh JH, Mladek AC, Burgenske DM, Regan MS, Baquer G, Decker PA, Carlson BL, Bakken KK, Zhang J, Liu L, Sun C, Mu Z, Zhong W, Tran NL, Elmquist WF, Agar NYR, Sarkaria JN, White FM. Conage-Pough JE, et al. Among authors: bakken kk. Neurooncol Adv. 2023 May 27;5(1):vdad066. doi: 10.1093/noajnl/vdad066. eCollection 2023 Jan-Dec. Neurooncol Adv. 2023. PMID: 37324218 Free PMC article.
Convection enhanced delivery of EGFR targeting antibody-drug conjugates Serclutamab talirine and Depatux-M in glioblastoma patient-derived xenografts.
Porath KA, Regan MS, Griffith JI, Jain S, Stopka SA, Burgenske DM, Bakken KK, Carlson BL, Decker PA, Vaubel RA, Dragojevic S, Mladek AC, Connors MA, Hu Z, He L, Kitange GJ, Gupta SK, Feldsien TM, Lefebvre DR, Agar NYR, Eckel-Passow JE, Reilly EB, Elmquist WF, Sarkaria JN. Porath KA, et al. Among authors: bakken kk. Neurooncol Adv. 2022 Aug 24;4(1):vdac130. doi: 10.1093/noajnl/vdac130. eCollection 2022 Jan-Dec. Neurooncol Adv. 2022. PMID: 36071925 Free PMC article.
Preclinical modeling in glioblastoma patient-derived xenograft (GBM PDX) xenografts to guide clinical development of lisavanbulin-a novel tumor checkpoint controller targeting microtubules.
Burgenske DM, Talele S, Pokorny JL, Mladek AC, Bakken KK, Carlson BL, Schroeder MA, He L, Hu Z, Gampa G, Kosel ML, Decker PA, Kitange GJ, Schmitt-Hoffmann A, Bachmann F, Vaubel RA, Eckel-Passow JE, Giannini C, McSheehy P, Lane HA, Elmquist WF, Sarkaria JN. Burgenske DM, et al. Among authors: bakken kk. Neuro Oncol. 2022 Mar 12;24(3):384-395. doi: 10.1093/neuonc/noab162. Neuro Oncol. 2022. PMID: 34232318 Free PMC article.
In Vivo Efficacy of Tesevatinib in EGFR-Amplified Patient-Derived Xenograft Glioblastoma Models May Be Limited by Tissue Binding and Compensatory Signaling.
Kizilbash SH, Gupta SK, Parrish KE, Laramy JK, Kim M, Gampa G, Carlson BL, Bakken KK, Mladek AC, Schroeder MA, Decker PA, Elmquist WF, Sarkaria JN. Kizilbash SH, et al. Among authors: bakken kk. Mol Cancer Ther. 2021 Jun;20(6):1009-1018. doi: 10.1158/1535-7163.MCT-20-0640. Epub 2021 Mar 30. Mol Cancer Ther. 2021. PMID: 33785646 Free PMC article.
16 results